SCHEMBL5286862

SCHEMBL5286862

CC1(C)CCN(S(=O)(=O)c2ccc(Cl)c3nonc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 7/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATM Q13315 1/20 0.41
SPR P35270 1/20 0.41
NPC1 O15118 1/20 0.39
TLR9 Q9NR96 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 3/20 0.39
MAPK1 P28482 2/20 0.39
HTT P42858 1/20 0.39
PKM P14618 1/20 0.38
RORA P35398 1/20 0.38
RORC P51449 1/20 0.38
NR1H2 P55055 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5297518 0.85 NPC1 (0.45) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL5286887 0.83 POLB (0.56) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL5285381 0.82 KMT2A (0.58) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL4785395 0.80 MAPT (0.55) LMNAALDH1A1KMT2AMEN1MAPT
SCHEMBL5243652 0.79 KMT2A (0.46) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL18711645 0.79 ALDH1A1 (0.55) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL5282272 0.78 TSHR (0.51) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL20960686 0.78 LMNA (0.42) LMNATDP1ALDH1A1KMT2AMEN1
SCHEMBL6391675 0.78 NPY5R (0.50)
SCHEMBL18701910 0.77 ALDH1A1 (0.49) LMNATDP1ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP LMNA 3860/4885TDP1 2234/4885ALDH1A1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.